Increased activity of endogenous endothelin in patients with type II diabetes mellitus
Increased activity of endogenous endothelin in patients with type II diabetes mellitus
复制标题
DOI：
10.1161/01.cir.0000032260.01569.64
复制
发表时间：
2002-10-01
期刊：
影响因子：
37.8
通讯作者：
Panza, JA
中科院分区：
文献类型：
--
作者：
Cardillo, C;Campia, U;Panza, JA
背景：内皮功能障碍可能增加糖尿病患者过早动脉粥样硬化的风险。内皮素（ET-1）可能通过激活平滑肌细胞有丝分裂和白细胞粘附参与了这一过程。我们试图通过使用ET-1受体拮抗剂来评估一组II型糖尿病患者内源性ET-1的活性。方法与结果：测定15例糖尿病患者和12例健康对照者动脉内输注ETA受体选择性阻滞剂（BQ-123）和不同情况下对ET-1的前臂血流量（171317）反应（应变计容积描记术）。另外，5例糖尿病患者联合输注BQ-123和BQ-788（一种选择性ETB受体阻滞剂）。在正常受试者中，BQ-123无显著差异。改变FBF （P=0.16）。相比之下，BQ-123在糖尿病患者中产生了显著的血管扩张反应(P
Background-Endothelial dysfunction may contribute to the risk of premature atherosclerosis in patients with diabetes. Endothelin (ET-1) may be involved in this process by activating smooth muscle cell mitogenesis and leukocyte adhesion. We sought to assess the activity of endogenous ET-1 in a group of patients with type II diabetes mellitus with the use of antagonists of ET-1 receptors.Methods and Results-Forearm blood flow (171317) responses (strain gauge plethysmography) to intraarterial infusion of a selective blocker of ETA receptors (BQ-123) and, on a different occasion, to ET-1, were measured in 15 patients with diabetes and 12 healthy controls. In addition, 5 patients with diabetes received coinfusion of BQ-123 and BQ-788 (a selective blocker of ETB receptors). In normal subjects, BQ-123 did not significantly. modify FBF from baseline (P=0.16). in contrast, BQ-123 administration resulted in a significant vasodilator response in patients with diabetes (P